X

Trial Profile

Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Heart Failure

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Empagliflozin (Primary)
Indications Heart failure
Focus Therapeutic Use
Acronyms EMBRACE-HF

Most Recent Events

10 Nov 2021 Status changed from active, no longer recruiting to completed.
18 Mar 2021 Planned End Date changed from 30 Jan 2021 to 30 Apr 2021.
08 Feb 2021 Primary endpoint has been met. (To compare the change in pulmonary artery diastolic pressure from baseline to end of treatment period between empagliflozin and placebo), as per Results published in the Circulation

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com